The Moroccan pharmaceutical industry marks an unprecedented milestone with the creation of the first cannabis-based drug entirely developed and manufactured in the country. As reported by the news outlet Hespress, the medicine was produced by the company Pharma 5 to treat severe forms of epilepsy resistant to conventional treatments, using an active ingredient obtained locally from the plant.

The active ingredient cannabidiol features a purification level exceeding ninety-eight percent and complies with the standards of the European Pharmacopoeia. The realization of the drug comes at the end of a five-year research and development program, accompanied by a financial investment that exceeded the threshold of two hundred million Moroccan dirhams.

The company specified that it manages the entire production chain, starting from regulated crops located in the Rif region up to the stages of extraction, purification, and packaging of the preparation. The initiative involves twenty hectares of land and provides a livelihood for seventy local families, using over ten tons of plant material processed according to pharmaceutical standards.

The project falls within the regulatory framework of Law 13-21, which governs the legal uses of cannabis in the country. The activity benefited from the collaboration of the National Agency for the Regulation of Cannabis-Related Activities and the Moroccan Agency for Medicines and Health Products, aiming at strengthening the national pharmaceutical sector.